Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Evaluation of Residual Anti-Xa Activity As A Function Of Time Following The Last Treatment Dose of Enoxaparin In Patients Presenting For Elective Surgery

NCT03296033 is registered in ClinicalTrials.gov with Wake Forest University Health Sciences as lead sponsor.

NCT NCT03296033
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03296033 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Evaluation of Residual Anti-Xa Activity As A Function Of Time Following The Last Treatment Dose of Enoxaparin In Patients Presenting For Elective Surgery
Lead sponsor
Wake Forest University Health Sciences
Phase
Phase 4
Overall status
Terminated
Start date
October 24, 2017
Completion date
January 14, 2022
Enrollment
122 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

anticoagulants and bleeding disorders, regional anesthesia morbidity, surgery